Jennifer K. Litton, MD: Patient Perspective on Talazoparib vs Chemotherapy for Breast Cancer

Posted: Monday, May 18, 2020

Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, talks about why EMBRACA trial patients with BRCA1/2-mutated HER2-negative advanced disease preferred talazoparib over chemotherapy, even though the PARP inhibitor did not improve overall survival compared with standard treatment.